Skip to main content
Smart Investors Daily
LG

NASDAQ · LGND

Ligand Pharmaceuticals Incorporated

Healthcare · Biotechnology

$286.94

Down-$11.77 (-3.94%)

Updated Nov 20, 2026, 2:38 AM

SID Score

5.4/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.6B
P/E ratio
99
Dividend yield
0.00%
52-week range
$175.89 – $326.63
Volume
168.87K
Avg. volume
207.76K

Price performance · LGND

LGND price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

LGND closed at $286.94 after 21 trading sessions, down 6.78% for the selected period.

Last close
$286.94
Period change
-6.78%
Period low
$286.94
Period high
$322.75
Daily close
View OHLC price history
LGND OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$300.09$301.72$286.00$286.94168.87K
Nov 18, 2026$295.00$301.93$292.94$298.71381.39K
Nov 17, 2026$300.26$302.02$291.605$293.81293.66K
Nov 16, 2026$311.51$313.755$300.55$301.71191.32K
Nov 13, 2026$313.98$314.79$308.59$308.79135.79K
Nov 12, 2026$316.57$325.89$310.0827$316.27248.3K
Nov 11, 2026$315.99$322.41$314.17$316.83126.8K
Nov 10, 2026$312.85$321.9799$310.41$314.16172.56K
Nov 9, 2026$310.34$315.80$307.135$314.15140.28K
Nov 6, 2026$302.02$308.26$297.835$306.20133.03K
Nov 5, 2026$316.57$318.98$297.63$299.00247.63K
Nov 4, 2026$319.00$319.99$309.86$316.13179.93K
Nov 3, 2026$309.99$317.76$307.5825$313.52195.59K
Nov 2, 2026$323.28$325.96$306.17$307.02265.43K
Oct 30, 2026$319.22$324.90$314.505$322.75344.31K
Oct 29, 2026$315.15$323.8248$309.63$317.33299.39K
Oct 28, 2026$311.62$319.90$309.69$318.78268.47K
Oct 27, 2026$308.51$314.19$307.55$311.73143.35K
Oct 26, 2026$304.39$309.43$303.47$308.30194.78K
Oct 23, 2026$307.82$313.28$302.37$303.53366.55K
Oct 22, 2026$313.00$315.2725$305.34$307.82315.14K

Latest LGND news

The latest Smart Investors Daily articles mentioning LGND.

LGND research

Overview

Company profile and research snapshot.

Company profile

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$245.33
Implied upside
—
Analysts
—
LGND recent ratings
DateFirmRatingTarget
Nov 11, 2026BarclaysOverweight—
Nov 5, 2026CitigroupBuy—
Oct 30, 2026RBC CapitalOutperform—
Sep 25, 2026BarclaysOverweight—
Sep 24, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.